title: Fibrin(ogen)olytic character of FIIa isolated from Agkistrodon acutus venom.
abstract: OBJECTIVE
  To investigate the fibrin(ogen)olytic character of FIIa isolated from Agkistrodon acutus venom in vitro and in vivo.
  
  
  METHODS
  125I-labeled human plasma clot lysis was measured in vitro and rabbit carotid artery thrombosis was as an in vivo model.
  
  
  RESULTS
  In vitro, urokinase (UK) at 25, 35, 40, 45, 60 kU/L and FIIa at 0.08, 0.23, 0.4, 0.5, and 0.7 g/L resulted an equivalent clot lysis (20%, 40%, 50%, 60%, and 80%). UK at 25 to approximately 60 kU/L induced 27.3%+/-3.6%, 35.2%+/-2.3%, 39.3%+/-2.4%, 44.2%+/-4.6%, and 51.1%+/-1.2% fibrinogen degradation. But FIIa at 0.08 approximately -0.7 g/L induced 95.4%+/-0.3%, >95.6%, >95.6%, >95.6%, >95.6% fibrinogen degradation respectively. In vivo, UK 40 kU/kg and FIIa 1.0 mg/kg reduced the weight of residual thrombus to 9.0+/-2.5 mg and 7.8+/-3.5 mg compared with negative control group (30.0+/-5.4 mg). But the fibrinogen degradation rate after UK 40 kU/kg and FIIa 1.0 mg/kg treatment was 24.4%+/-6.2% and 4.1%+/-7.8%, respectively (P<0.05, n=6). The order of the lysis speed after UK 125 kU/L treatment was platelet poor plasma (PPP) clots>the whole blood clots>platelet rich plasma (PRP) clots. The sequence for FIIa 0.4 g/L was PRP >PPP >whole blood clots.
  
  
  CONCLUSIONS
  At the same percentage of clot lysis, FIIa degraded more fibrinogen than UK did in vitro but less fibrinogen than UK did in vivo. The order of the lysis speed was PPP>whole blood clots>PRP clots for UK and PRP>PPP>whole blood clots for FIIa.
authors.affiliation: Department of Pharmacology, Zhongshan Medical College, Sun Yat-sen University, Guangzhou 510080, China.
authors.forename: Yi-wen
authors.initials: YW
authors.lastname: Wang
authors.forename: Xiu-xia
authors.initials: XX
authors.lastname: Liang
authors.forename: Jia-shu
authors.initials: JS
authors.lastname: Chen
authors.forename: Qi
authors.initials: Q
authors.lastname: Chen
authors.forename: Peng-xin
authors.initials: PX
authors.lastname: Qiu
authors.forename: Xi
authors.initials: X
authors.lastname: Lin
authors.forename: Guang-mei
authors.initials: GM
authors.lastname: Yan
mesh_terms: D017836:Agkistrodon; D000818:Animals; D002341:Carotid Artery Thrombosis / Q000503:physiopathology*; D003435:Crotalid Venoms / Q000008:administration & dosage / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology; D008297:Male; D008666:Metalloendopeptidases; D011817:Rabbits; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology
chemical_list: D003435:Crotalid Venoms; D005343:Fibrinolytic Agents; D014568:Urokinase-Type Plasminogen Activator; C478420:FIIa; D008666:Metalloendopeptidases